drugset
drugset / Trial / NCT02808026

Study of CS-3150 in Patients With Severe Hypertension

NCT02808026 ↗

Phase 3 Completed 20 enrolled Daiichi Sankyo
NaSingle-groupOpen-labelTreatment

Summary

To examine antihypertensive effect and safety of administration of CS-3150 in patients with severe hypertension (Grade III).

Timeline

Start
2016-06
Primary completion
2017-02
Completion
2017-02

Drugs

EvaluationDrugModalityDoseRoute
Subject CS-3150 Unknown 2.5 mg Oral
Subject CS-3150 Unknown 5 mg Oral

Indications

hypertensive disorder